You are here

  • Home
  • Online First
  • Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by Sparks et al

Article info

Article menu
Download PDFPDF
Correspondence response
Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by Sparks et al

Authors

  • Zachary S Wallace Massachusetts General Hospital, Boston, Massachusetts, USAHarvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Jeffrey A Sparks Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USAMedicine, Harvard Medical School, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Philip C Robinson Faculty of Medicine, The University of Queensland, Herston, Queensland, AustraliaMetro North Hospital & Health Service, Royal Brisbane and Woman's Hospital Health Service District, Herston, Queensland, Australia PubMed articlesGoogle scholar articles
  • Pedro M Machado MRC Centre for Neuromuscular Diseases, University College London, London, UKRheumatology, University College London Centre for Rheumatology, London, UK PubMed articlesGoogle scholar articles
  • Jinoos Yazdany Medicine/Rheumatology, University of California San Francisco, San Francisco, California, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Jeffrey A Sparks, Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA 02115, USA; jsparks{at}bwh.harvard.edu
View Full Text

Citation

Wallace ZS, Sparks JA, Robinson PC, et al
Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by Sparks et al
Annals of the Rheumatic Diseases Published Online First: 23 August 2021. doi: 10.1136/annrheumdis-2021-220960

Publication history

  • Received July 9, 2021
  • Accepted July 11, 2021
  • First published August 23, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage